Zacks Research Has Bearish Forecast for HALO Q1 Earnings
Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report) – Research analysts at Zacks Research decreased their Q1 2027 EPS estimates for shares of Halozyme Therapeutics in a research note issued on Tuesday, April 29th. Zacks Research analyst R. Department now expects that the biopharmaceutical company will post earnings of $1.83 per share for the quarter, down […]
Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report) – Research analysts at Zacks Research decreased their Q1 2027 EPS estimates for shares of Halozyme Therapeutics in a research note issued on Tuesday, April 29th. Zacks Research analyst R. Department now expects that the biopharmaceutical company will post earnings of $1.83 per share for the quarter, down […]
